Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23751145 | 0.93 | HRH3 (0.34) | S1PR1KMT2AHRH3ABCB1 | |
| SCHEMBL23751164 | 0.91 | HRH3 (0.33) | S1PR1HRH3ABCB1 | |
| SCHEMBL29372226 | 0.91 | NR1H2 (0.40) | S1PR1MAPT | |
| SCHEMBL22772343 | 0.89 | HRH3 (0.35) | MAPTMEN1KMT2AHRH3ALDH1A1 | |
| SCHEMBL22772329 | 0.89 | HRH3 (0.35) | KMT2AHRH3ABCB1 | |
| SCHEMBL23751241 | 0.87 | F10 (0.36) | MAPTMEN1KMT2AHRH3ALDH1A1 | |
| SCHEMBL23751254 | 0.87 | F10 (0.37) | MAPTKMT2AHRH3ABCB1 | |
| SCHEMBL23751117 | 0.86 | HRH3 (0.35) | HRH3ABCB1 | |
| SCHEMBL23751200 | 0.85 | F10 (0.33) | MAPTMEN1KMT2AHRH3ALDH1A1 | |
| SCHEMBL23762153 | 0.83 | NR1H2 (0.40) | MAPTHRH3ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-05-17 | — | — | US | disclosed |
| EP-3728248-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-02-02 | — | — | EP | disclosed |
| US-20200392133-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | ROCK1, ROCK2, RHOA | S1PR1 956/4885MAPT 2490/4885MEN1 3170/4885 |
| US-20200392133-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | S1PR1 956/4885MAPT 2490/4885MEN1 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.